• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Covidien’s SpiderFX wins FDA clearance | Regulatory Roundup

Covidien’s SpiderFX wins FDA clearance | Regulatory Roundup

December 1, 2011 By MassDevice staff

Covidien SpiderFX

SpiderFX embolic protection device

Covidien (NYSE:COV) landed 510(k) clearance for its SpiderFX system to treat severely calcified lesions in the lower extremities.

The Mansfield, Mass.-based med-tech titan’s system has been on the European market since 2005 and is currently the only embolic protection device indicated for use in the lower extremities in the U.S.

Covidien sought 510(k) approval from the federal watchdog agency based on results of its 133 subject Definitive Ca++ clinical study, which showed that the SpiderFX system could be used in conjunction with plaque excision to treat severely calcified lesions in arteries of the lower extremities,

Sign up to get our free newsletters delivered straight to your inbox

The SpiderFX system was tested with Covidien’s TurboHawk plaque excision device, which won FDA approval in January.

"The expanded indication of these devices offers interventionalists a safer option for dealing with severely calcified lesions. In complex cases, this technology shows promise of being a positive step forward for treating patients with peripheral arterial disease," Daniel Clair, professor of surgery at Cleveland Clinic Lerner College of Medicine said in prepared remarks.

The news from the FDA hasn’t done much for COV on Wall Street, where shares are only up 2 percent at $46.40 in mid-morning trading versus $45.55 at market close yesterday.

Late last month, Covidien acquired med-tech maker Barrx Medical for $325 million.

Sunnyvale, Calif.-based Barrx specializes in minimally invasive radiofrequency ablation systems that target precancerous tissue in the esophagus.

Covidien will acquire all outstanding Barrx stock in a deal slated to close by January 31, 2012.

Regulatory Roundup
  • FDA establishes new product codes
    The FDA established new product codes for interbody devices with integrated Fixation. RBS Spine received a revised FDA clearance letter for its InterPlate system yesterday.
    Read more

  • CardioInsight announces CE Mark of Ecvue
    Cleveland, Ohio-based CardioInsight Technologies Inc. won CE Mark approval for its Ecvue system to help diagnose cardiac arrhythmias.
    Read more
  • Riverain Technologies lands PMA for OnGuard update
    Riverain Technologies landed PMA supplemental approval from the federal watchdog agency for a software update on its OnGuard computer-aided detection system.
    Read more
  • Feeding tube cleared by FDA
    Applied Medical Technology’s "Low-profile transgastric-Jejunal feeding tube kit" was listed on the FDA’s 510(k) clearance list for October.
    Read more

Filed Under: 510(k), Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA) Tagged With: Applied Medical Technology, CardioInsight Technologies Inc., Covidien, Regulatory Roundup, Riverain Medical

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy